<DOC>
	<DOCNO>NCT00089284</DOCNO>
	<brief_summary>Monoclonal antibody rituximab yttrium Y 90 ibritumomab tiuxetan locate cancer cell either kill deliver radioactive cancer-killing substance without harm normal cell . Motexafin gadolinium may increase effectiveness yttrium Y 90 ibritumomab tiuxetan make cancer cell sensitive drug . This phase I/II trial study side effect best dose motexafin gadolinium administer rituximab yttrium Y 90 ibritumomab tiuxetan see well work treat patient stage II , stage III , stage IV relapse refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Phase I/II Trial Redox Regulation Patients With Relapsed Refractory CD20+ NHL</brief_title>
	<detailed_description>This phase I , dose-escalation study motexafin gadolinium follow phase II study . Patients stratify accord extent lymphomatous involvement ( ≤ 5 % v &gt; 5 ≤ 24 % cellular element ) . Cohorts 3-6 patient stratum receive escalating dos motexafin gadolinium maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity ( DLT ) OR dose precede 2 3 3 6 patient experience DLT . - Once MTD determine , additional patient treat dose level phase I . Patients follow weekly 3 month monthly 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis one following : Lowgrade follicular Bcell nonHodgkin 's lymphoma ( NHL ) The following histology eligible : Small lymphocytic lymphoma Lymphoplasmacytoid lymphoma Follicular center grade 1 , 2 , 3 lymphoma Extranodal marginal zone Bcell lymphoma mucosaassociated lymphoid tissue type Nodal marginal zone Bcell lymphoma Relapsed refractory 2 prior treatment regimens 1 anthracycline regimen Diffuse large Bcell NHL mantle cell lymphoma first second relapse Transformed NHL , define lowgrade NHL transform diffuse large Bcell lymphoma , 1 relapse since transformation Age 18 Recovered prior immunotherapy Life expectancy At least 3 month Recovered prior chemotherapy More 4 week since prior major surgery recover More 4 week since prior anticancer therapy recover prior radiotherapy Exclusion criterion : No major bleeding within past 4 week No uncontrolled hypertension No stroke within past 4 week No active infection No active nonmalignant disease No know G6PD deficiency No history porphyria No condition would preclude study participation No human antimouse antibodies No known history HIV Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior radioimmunoconjugate therapy No prior exposure murine antibody rituximab More 4 week since prior rituximab No history fail stem cell collection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>